Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients

NCT00511459 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

228

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Recurrent and Metastatic Breast Cancer

Interventions

DRUG: AMG 386 Placebo
DRUG: AMG 386
DRUG: Bevacizumab
DRUG: AMG 386
DRUG: AMG 386
DRUG: Paclitaxel

Sponsor

Amgen